Cargando…
Phase 1 trial for treatment of COVID‐19 patients with pulmonary fibrosis using hESC‐IMRCs
Autores principales: | Wu, Jun, Zhou, Xing, Tan, Yuanqing, Wang, Liu, Li, Tianda, Li, Zhongwen, Gao, Tingting, Fan, Jiaqi, Guo, Baojie, Li, Wei, Hao, Jie, Wang, Xianguang, Hu, Baoyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645925/ https://www.ncbi.nlm.nih.gov/pubmed/33107132 http://dx.doi.org/10.1111/cpr.12944 |
Ejemplares similares
-
First case of COVID‐19 infused with hESC derived immunity‐ and matrix‐regulatory cells
por: Wu, Jun, et al.
Publicado: (2020) -
Hyaluronate supports hESC‐cardiomyocyte cell therapy for cardiac regeneration after acute myocardial infarction
por: Tan, Yuanqing, et al.
Publicado: (2020) -
Genome editing HLA alleles for a pilot immunocompatible hESC line in a Chinese hESC bank for cell therapies
por: Ji, Tian‐Tian, et al.
Publicado: (2023) -
hESC-derived immune suppressive dendritic cells induce immune tolerance of parental hESC-derived allografts
por: Todorova, Dilyana, et al.
Publicado: (2020) -
A Chemical Recipe for Generation of Clinical-Grade Striatal Neurons from hESCs
por: Wu, Menghua, et al.
Publicado: (2018)